CPIX - Cumberland Pharmaceuticals Inc logo

Cumberland Pharmaceuticals Inc

CPIX

Cumberland Pharmaceuticals develops and commercializes prescription products, including Acetadote for acetaminophen poisoning and Caldolor for pain and fever. It serves the hospital, gastroenterology, and oncology markets across multiple countries.

โš•๏ธ Healthcare NASDAQ Listed 2009 $ USD
$1,000 invested 10 years ago โ†’$2,811today

Score Overview

1 Year
Score
Net Growth-273.98%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-29.77%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score2.3
Net Growth-202.39%
Net Trend20%
Net Income Consistencyโ€”
Rev Growth-13.11%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-9x
Net Trend40%
Net Income Consistency
Rev Growth-5.32%
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth-443.09%
Net Trend41%
Net Income Consistency
Rev Growth-28.18%
Rev Trend41%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Cumberland Pharmaceuticals Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • CPIX

2020: 96.0% ยท 2021: 92.2% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 8.48โ€”
1 Year2025-10-22
$ 2.12300.49%
5 Years2021-10-22
$ 1.64417.04%
10 Years2016-10-21
$ 3.02181.07%
All Time2009-08-11
$ 10.30-17.67%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 31M-$ 10M$ 3M
2025$ 44M-$ 2M$ 11M
2024$ 37M-$ 6M$ 17M
2023$ 39M-$ 6M$ 18M
2022$ 42M-$ 5M$ 19M
2021$ 35M-$ 3M$ 27M
2020$ 37M-$ 3M$ 24M
2019$ 34M-$ 3M$ 28M
2018$ 40M-$ 6M$ 36M
2017$ 41M-$ 7M$ 50M
2016$ 33M-$ 944.68K$ 50M
2015$ 33M$ 731.35K$ 52M
2014$ 36M$ 2M$ 54M
2013$ 32M-$ 2M$ 54M
2012$ 48M$ 5M$ 71M
2011$ 51M$ 5M$ 70M
2010$ 45M$ 2M$ 65M
IPO2009$ 43M$ 3M$ 78M
CPIX - Cumberland Pharmaceuticals Inc logo

Cumberland Pharmaceuticals Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 37M to $ 44M and net income went from -$ 3M to -$ 2M. Revenue increased in 2 of those 5 years; net income in 1.

Across Cumberland Pharmaceuticals Inc's full reported history, from 2009 to 2025, revenue grew from $ 43M to $ 44M and net income went from $ 3M to -$ 2M. Revenue increased in 41% of the years measured; net income in 41%.

Cumberland Pharmaceuticals Inc currently holds a 5-year HDB Score of 2.3 out of 10. How the HDB Score is calculated.

Membership

Continue CPIXโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies